Sun Pharma Advances MM-II for Osteoarthritis Relief

On June 14, 2024, Sun Pharma and Moebius Medical revealed new findings at EULAR 2024. They shared data showing that patients with symptomatic knee osteoarthritis continued to experience significant pain relief up to 26 weeks after receiving injections of MM-II. These results come from a Phase 2b clinical trial (NCT04506463) that included randomised and controlled testing.

Philip G. Conaghan, Professor of Musculoskeletal Medicine at the University of Leeds and Director of the NIHR Leeds Biomedical Research Centre, presented findings from a study titled “Duration of Clinically Meaningful Analgesic Response to Intra-Articular MM-II in Patients with Painful Knee Osteoarthritis.” The study focused on MM-II, a novel suspension of large, empty, multilamellar liposomes.

Prof. Conaghan highlighted that the 3mL dose of MM-II in the trial showed promising potential to provide lasting and significant pain relief, addressing a critical need for effective therapies in osteoarthritis management.

MM-II is a new non-opioid treatment created by Sun Pharma and Moebius Medical. It uses a special suspension of large, empty, multilamellar liposomes designed to lessen joint friction and wear, which helps ease joint pain. The companies have announced their intention to start a Phase 3 clinical trial and apply for this product’s CE Mark in the European Union.

Abhay Gandhi, CEO of North America Business, Sun Pharma, commented, “With over 100 million people currently suffering from joint pain, there is a significant unmet need for additional OA therapies. This analysis from our clinical trial further confirms the potential role that MM-II can play in improving painful OA treatment.”

About Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited, established in 1993, is a leading global company specialising in speciality generics and healthcare products. Based in India, it is the largest pharmaceutical firm in the country and holds a prominent position in the US and other emerging markets worldwide. The company operates integrated facilities across six continents, ensuring healthcare professionals and consumers trust high-quality medicines in more than 100 countries. Sun Pharma takes pride in its multicultural workforce, which comprises individuals from over 50 nations.

On June 14, 2024, Sun Pharmaceutical Industries Limited’s share price on the NSE opened at ₹1,513.85 and closed at ₹1,515.00.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.